论文部分内容阅读
目的探讨血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和肿瘤特异性生长因子(TSGF)在肺癌化疗前后的水平变化及疗效评估价值。方法选取80例接受紫杉醇联合吉西他滨化疗的肺癌患者,应用电化学发光免疫分析技术和生化比色法,检测化疗前及化疗21天后患者血清中CEA、CYFRA 21-1和TSGF水平变化。结果患者血清中CEA、CYFRA 21-1和TSGF的水平在紫杉醇联合吉西他滨化疗后显著降低,差异具有统计学意义(P<0.05)。且患者血清中CEA、CYFRA 21-1和TSGF水平变化与紫杉醇联合吉西他滨的化疗疗效具有明显的统计相关性。结论肺癌患者应用紫杉醇联合吉西他滨化疗可明显降低血清CEA、CYFRA 21-1和TSGF水平,说明CEA、CYFRA 21-1和TSGF在临床肺癌治疗效果的评估中具有重要的意义。
Objective To investigate the serum levels of carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and tumor specific growth factor (TSGF) before and after chemotherapy in lung cancer and evaluate the efficacy of evaluation. Methods Eighty cases of lung cancer patients receiving paclitaxel combined with gemcitabine chemotherapy were used to detect the changes of serum CEA, CYFRA 21-1 and TSGF levels before and 21 days after chemotherapy using electrochemiluminescence immunoassay and biochemical colorimetry. Results The levels of CEA, CYFRA 21-1 and TSGF in the serum of patients were significantly decreased after paclitaxel plus gemcitabine chemotherapy. The difference was statistically significant (P<0.05). The change of CEA, CYFRA 21-1 and TSGF levels in the serum of patients was significantly correlated with the chemotherapy effect of paclitaxel plus gemcitabine. Conclusion The use of paclitaxel combined with gemcitabine chemotherapy in lung cancer patients can significantly reduce the serum levels of CEA, CYFRA 21-1 and TSGF, indicating that CEA, CYFRA 21-1 and TSGF are of great significance in the evaluation of clinical lung cancer treatment.